Bausch Health, Canada Inc. has announced that its medication SILIQ® (brodalumab injection), utilized for the treatment of moderate to severe plaque psoriasis, is now reimbursed by Alberta's public drug plan. This decision aims to increase accessibility for eligible patients who may benefit from this therapy. SILIQ®, which functions as an interleukin-17 receptor antagonist, provides a new treatment option for those who have not responded adequately to other systemic therapies.
The inclusion of SILIQ® in the provincial drug reimbursement schedule reflects an ongoing effort to improve access to necessary medications for patients with chronic health conditions, such as plaque psoriasis. The new status under the public drug plan allows for reduced out-of-pocket costs for patients, potentially leading to better health outcomes.
Bausch Health expressed optimism regarding the approved reimbursement, highlighting the importance of offering innovative treatment for patients in Alberta. With this approval, the company envisions that more individuals will be able to manage their psoriasis effectively and improve their quality of life, which can significantly impact their daily functioning and mental health.
As Alberta joins other provinces in facilitating access to SILIQ®, discussions about public drug coverage for other treatments continue to display the necessity of balancing cost and availability of advanced healthcare options in Canada. Stakeholders in Alberta's healthcare landscape are encouraged to monitor the breadth of treatment options available as more therapies receive coverage under public plans.
Analyzed Canadian Outlets (1)
1 headline